Log In Sign up
The largest database of trusted experimental protocols

Anti tfpi2

Manufactured by Santa Cruz Biotechnology
Visit Supplier
Sourced in Japan

Anti-TFPI2 is a laboratory product used for research purposes. It is an antibody that specifically targets the tissue factor pathway inhibitor 2 (TFPI2) protein. The core function of this product is to provide researchers with a tool to detect and study the TFPI2 protein in various experimental settings.

Automatically generated - may contain errors

Lab products found in correlation

Immobilon pvdf membrane, by Merck Group (1 mentions) Gel pro analyzer software, by Media Cybernetics (1 mentions) Anti mouse igg hrp, by Merck Group (1 mentions) Ecl blocking reagent, by GE Healthcare (1 mentions) Anti α tubulin, by Merck Group (1 mentions) Ecl prime, by GE Healthcare (1 mentions) Bradford protein assay, by Bio-Rad (1 mentions) Anti β actin, by Santa Cruz Biotechnology (1 mentions) Anti lsd1, by Abcam (1 mentions) Anti tgfbr2, by Santa Cruz Biotechnology (1 mentions) Anti tgfbr1, by Santa Cruz Biotechnology (1 mentions) Anti smad7, by Santa Cruz Biotechnology (1 mentions) Cell lysis buffer, by Beyotime (1 mentions)

3 protocols using anti tfpi2

1

Western Blot Quantification Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Protein concentrations were measured using the Bio-Rad Bradford protein assay. The proteins were separated by 12% SDS-polyacrylamide gel electrophoresis, transferred to IMMOBILON PVDF membranes (Millipore) and incubated overnight at 4°C in blocking buffer containing 2% ECL blocking reagent (GE Healthcare) and 0.1% Tween 20 in PBS. The membranes were probed with either anti TFPI-2 (1:500, SantaCruzBiotechnology) or anti α-tubulin (1:1000, Sigma-Aldrich) antibody for 1h at room temperature. Antibody binding was detected with anti-mouse IgG-HRP (1:10,000, Sigma Aldrich) for 45min at room temperature. The signals were detected with ECL Prime (GE-Healthcare). Densitometry of protein bands was analysed with GelPro Analyzer Software (Media Cybernetics).
Ghilardi C., Silini A., Figini S., Anastasia A., Lupi M., Fruscio R., Giavazzi R, & Bani M. (2015). Trypsinogen 4 boosts tumor endothelial cells migration through proteolysis of tissue factor pathway inhibitor-2. Oncotarget, 6(29), 28389-28400.
+ Open protocol
+ Expand
2

Western Blotting of HEK293 Cell Lysates

Check if the same lab product or an alternative is used in the 5 most similar protocols
Western blotting of HEK293 lysates were done as described previously46 (link). Antibodies were rabbit anti-KDM5A (NB110-40499; Novus Biologicals Inc., Centennial, USA; 1:2,000 dilution), anti-LSD1 (ab17721; Abcam Inc., Cambridge, UK; 1:2,000 dilution), anti-Flag (M185; MBL Inc., Nagoya, Japan; 1:2,000 dilution), anti-TFPI2 (sc-48380; Santa Cruz Biotechnology Inc., Santa Cruz, CA; 1:1,000 dilution), or anti-β-actin (sc-47778; Santa Cruz Biotechnology Inc.; 1:1,000 dilution).
Mitsui E., Yoshida S., Shinoda Y., Matsumori Y., Tsujii H., Tsuchida M., Wada S., Hasegawa M., Ito A., Mino K., Onuki T., Yoshida M., Sasaki R, & Mizukami T. (2019). Identification of ryuvidine as a KDM5A inhibitor. Scientific Reports, 9, 9952.
+ Open protocol
+ Expand
3

Immunoprecipitation of TFPI2, SMAD7, TGFBR1, TGFBR2

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cells were lysed with cell lysis buffer (#P0013, Beyotime). Whole cell lysates were obtained after centrifugation, and protein concentration was determined. The protein extracts were diluted to 1 μg/μl in phosphate buffer saline (PBS) and then incubated with 1 μg of the indicated antibody and 60 μl protein A agarose beads for 2 h at 4 °C. The antibodies for IP include anti-TFPI2 (#sc-48380; Santa Cruz), anti-SMAD7 (#sc-101152, Santa Cruz), anti-TGFBR1 (#sc-518018, Santa Cruz), and anti-TGFBR2 (#sc-17792, Santa Cruz). IgG was used as a negative control. Immunocomplexes obtained by centrifugation were separated by SDS-PAGE, and immunoblotting was performed as previously described.
Guan G., Xie J., Dai Y, & Han H. (2022). TFPI2 suppresses the interaction of TGF-β2 pathway regulators to promote endothelial–mesenchymal transition in diabetic nephropathy. The Journal of Biological Chemistry, 298(3), 101725.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!